CemiplimAb Survivorship Epidemiology
NCT03836105
·
clinicaltrials.gov ↗
COMPLETED
Status
287
Enrollment
INDUSTRY
Sponsor class
Conditions
Cutaneous Squamous Cell Carcinoma
Basal Cell Carcinoma
Interventions
DRUG:
cemiplimab
Sponsor
Regeneron Pharmaceuticals